Other studies publikationen

PAPI Study

  1. Wetzke M, Le DB, Tometten I, Ritter S, Lübke N, Timm J, Dilthey A, Panning M, Walker A, Happle C. (2025) Prevalence of Resistance-Associated Mutations in RSV F Protein Against Monoclonal Antibodies Prior to Widespread Implementation: Findings From a Prospective German Pediatric Cohort. Influenza Other Respiratory Viruses . 19(9):e70164.  doi: 10.1111/irv.70164 .

  2. Bähre J, Lange M, Salaschek P, Twardella D, Arens S, Eberhard F, Barten- Neiner G, Panning M, Köster H, Körner-Rettberg C, Wetzke M, Happle C. (2025)  Distinct seasonality and increased respiratory failure in RSV patients < 2 years of age after emergence of SARS-CoV-2: data from the multicentric, prospective PAPI study.  Eur J Pediatr.  184(4):246.  doi: 10.1007/s00431-025-06057-0 .

  3. Wetzke M, Lange M, Koerner-Rettberg C, Kiefer A, Kabesch M, Armbrust S, Abdelkhalek K, Lex C, Hufnagel M, Bode S, Dördelmann M, Lorenz M, Arens S, Panning M, Köster H, Kramer R, Bangert M, Eberhardt F, Barten- Neiner G, Happle C. (2025) RSV is the main cause of severe respiratory infections in infants and young children in Germany – data from the prospective, multicenter PAPI study 2021-2023. Infection.  53(5):1715-1723.  doi:  10.1007/s15010-025-02484-1

 

Pulmonary Emphysema Registry eV

  1. Saccomanno J, Sgarbossa T, Neumann K, Stanzel F, Andreas S, Eisenmann S, Schmidt B, Gesierich W, Witzenrath M, Hübner RH; Lung Emphysema study group. (2025).  Limited Benefit of Additional Chartis® Assessments for Collateral Ventilation Evaluation in Patients with Software 
    Quantified Intact Target Lobe Fissure – Results from a Retrospective Analysis of the German Lung Emphysema Registry.     Int J Chron Obstruct Pulmon Dis . 20:3939-3950.      doi: 10.2147/COPD.S538587.

  2. Saccomanno J, Elgeti T, Spiegel S, Pappe E, Sgarbossa T, Petersen A, Neumann K, Mall MA, Witzenrath M, Hübner RH. (2025)  Association of Mucus Plugging and Body Mass Index in Patients With Advanced COPD GOLD 3/4 With Emphysema. Chronic Obstr Pulm Dis .  2(6):490-499.  doi: 10.15326/jcopdf.2025.0617

  3. Saccomanno J, Kilic L, Sgarbossa T, Neumann K, Stanzel F, Holland A, Grah C, Gesierich W, Krist J, Ficker JH, Eggeling S, Andreas S, Schmidt B, Eisenmann S, Schwick B, Franke KJ, Fertl A, Witzenrath M, Hübner RH. (2025)  Clinical improvements after endoscopic lung volume reduction with valves in patients with advanced emphysema and a 6-min walk test ≤140 m at baseline. ERJ Open Res 11(1):00410-2024.  doi: 10.1183/23120541.00410-2024

  4. Atug E, Trudzinski FC, Holland A, Grah C, Huebner RH, Stanzel F, Eggeling S, Schmidt B, Kurz S, Eisenmann S, Krist J, Ficker J, Wiesemann B, Gesierich W, Eberhardt R; German Lung Emphysema Registry Study Group. (2025). Sex differences in outcome after endoscopic lung volume reduction
    (ELVR) in patients with emphysema: a retrospective analysis of the German Lung Emphysema Registry (LER e.V.).     Thorax.  thorax-2025-223559. doi: 10.1136/thorax-2025-223559.

  5. Grah C, Oei SL, Krist J, Wiesemann B, Schmidt B, Fertl A, Schwick B, Hübner RH, Becke B, Franke KJ, Geltner C, Eisenmann S, Stanzel F, Barten- Neiner G, Sgarbossa T, Blazejczyk K, Wüstefeld H. (2025) Efficacy and Safety of Lung Volume Reduction with Endobronchial Coil #2 and Coil #4 Results of the German Emphysema Registry-Lungenemphysemaregister eV COPD 22(1):2468328. doi: 10.1080/15412555.2025.2468328

  6. Rummenholl M, Sgarbossa T, Grah C, Holland A, Hübner RH. Das Lungenemphysemregister e.V.: Verbesserung der Versorgungsqualität bei
    interventioneller Emphysemtherapie und Gesundheitsmanagement für Patient*innen mit fortgeschrittener COPD und Lungenemphysem [The Lung Emphysema Registry: Improving quality of care in interventional emphysema therapy and health management for patients with advanced COPD and lung emphysema]    . Pneumologie 79(9):661-666. German. doi: 10.1055/a-2532-4885

  7. Sgarbossa T, Borchers P, Saccomanno J, Ahrens K, Wüstefeld HF, Pappe E, Wuelfing U, Klein U, Witzenrath M, Stanzel F, Grah C, Hübner RH. (2025) Comparison of Efficacy and Safety of Different Types of One-Way Valves in Endoscopic Lung Volume Reduction in Patients with Severe Lung Emphysema. Respiration 104(4):281-289. doi: 10.1159/000542806

  8. Saccomanno J, Sgarbossa T, Pappe E, Kilic L, Biglari S, Shargill NS, Radhakrishnan S, Witzenrath M, Hübner RH. (2024) VT20 method for Chartis assessment of collateral ventilation with flexible bronchoscopy under procedural sedation. ERJ Open Res. 10(4):00945-2023. doi: 10.1183/23120541.00945-2023

  9. Pappe E, Hübner RH, Saccomanno J, Ebrahimi HDN, Witzenrath M, Wiessner A, Sarbandi K, Xiong Z, Kursawe L, Moter A, Kikhney J. (2024)  Biofilm infections of endobronchial valves in COPD patients after endoscopic lung volume reduction: a pilot study with FISHseq. Sci Rep  14(1):23078.  doi: 10.1038/s41598-024-73950-3 

  10. Sgarbossa T, Lenga P, Stanzel F, Holland A, Grah C, Gesierich W, Gebhardt A, Ficker J, Eggeling S, Andreas S, Schmidt B, Eisenmann S, Schwick B, Franke KJ, Fertl A, Witzenrath M, Hübner RH. (2023)  Assessment of efficacy and safety of endoscopic lung volume reduction with one-way valves in patients with a very low FEV1.  ERJ Open Res 9(4):00190-2023.  doi: 10.1183/23120541.00190-2023 

  11. Pappe E, Hammerich R, Saccomanno J, Sgarbossa T, Pohrt A, Schmidt B, Grah C, Eisenmann S, Holland A, Eggeling S, Stanzel F, Witzenrath M,  Hübner RH. (2023)  Impact of Coronavirus Disease 2019 on Hospital Admissions, Health Status, and Behavioral Changes of Patients with COPD.  Chronic Obstr Pulm Dis.  10(3):211-223.  doi: 10.15326/jcopdf.2022.0383

  12. Saccomanno J, Ruwwe-Glosenkamp C, Neumann K, Doellinger F, Lenga P, Pappe E, Suttorp N, Witzenrath M, Hübner RH. (2022)  Impact of Ventilation Modes on Bronchoscopic Chartis Assessment Outcome in Candidates for Endobronchial Valve Treatment. Respiration 101(4):408–416.  doi: 10.1159/000520082

  13. Lenga P, Grah C, Ruwwe-Glösenkamp C, Saccomanno J, Rückert J, Eggeling S, Gläser S, Kurz S, Eisenmann S, Krüger M, Schmidt B, Schneider P, Andreas S, Hinterthaner M, Pfannschmidt J, Gebhardt A, Stanzel F, Holland A, Kirschbaum A, Becke B, Hübner RH. (2022).  Lung Emphysema Registry Study Group. Endoscopic Lung Volume Reduction with One-Way Valves in Patients with Severe Chronic Obstructive Pulmonary Disease with Hypercapnia.  Respiration.  101(9):823-832.  doi: 10.1159/000524996. 

PROGNOSIS Studie

  1. van Ingen J, Aliberti S, Andrejak C, Chalmers JD, Codecasa LR, Daley CL, Hasegawa N, Griffith DE, Hoefsloot W, Huitt G, Jarand J, Jhun BW, Loebinger MR, Marras TK, Morimoto K, Polverino E, Ringshausen FC, Santin M, Thomson R, Wagner D, Wallace RJ, Winthrop KL, Yim JJ. (2021). Management of Drug Toxicity in Mycobacterium avium Complex Pulmonary Disease: An Expert Panel Survey. Clin Infect Dis. 73(1):e256-e259. doi: 10.1093/cid/ciaa1361.
  2. Loebinger MR, Polverino E, Chalmers JD, Tiddens HAWM, Goossens H, Tunney M, Ringshausen FC, Hill AT, Pathan R, Angyalosi G, Blasi F, Elborn SJ, Haworth CS; iBEST-1 Trial Team. (2021). Efficacy and safety of TOBI Podhaler in Pseudomonas aeruginosa-infected bronchiectasis patients: iBEST study. Eur Respir J. 57(1):2001451. doi: 10.1183/13993003.01451-2020.
  3. Rademacher J, Konwert S, Fuge J, Dettmer S, Welte T, Ringshausen FC. (2020) Anti-IL5 and anti-IL5Rα therapy for clinically significant bronchiectasis with eosinophilic endotype: a case series. Eur Respir J. 55(1):1901333. doi: 10.1183/13993003.01333-2019.
  4. Ringshausen FC, Rademacher J, Pink I, de Roux A, Hickstein L, Ploner T, Welte T, Diel R. (2019). Increasing bronchiectasis prevalence in Germany, 2009-2017: a population-based cohort study. Eur Respir J. 54(6):1900499. doi: 10.1183/13993003.00499-2019.
  5. Shteinberg M, Crossley B, Lavie T, Nadler S, Boyd J, Ringshausen FC, Aksamit T, Chalmers JD, Goeminne P. (2019). Recommendations for travelling with bronchiectasis: a joint ELF/EMBARC/ERN-Lung collaboration. ERJ Open Res. 5(4):00113-2019. doi: 10.1183/23120541.00113-2019.
  6. Chalmers JD, Ringshausen FC, Harris B, Elborn JS, Posthumus A, Haworth CS, Pilkington N, Polverino E, Ruddy T, Aliberti S, Goeminne PC, Winstanley C, De Soyza A. (2018). Cross-infection risk in patients with bronchiectasis: a position statement from the European Bronchiectasis Network (EMBARC), EMBARC/ELF patient advisory group and European Reference Network (ERN-Lung) Bronchiectasis Network. Eur Respir J. 51(1):1701937. doi: 10.1183/13993003.01937-2017
  7. Hill AT, Haworth CS, Aliberti S, Barker A, Blasi F, Boersma W, Chalmers JD, De Soyza A, Dimakou K, Elborn JS, Feldman C, Flume P, Goeminne PC, Loebinger MR, Menendez R, Morgan L, Murris M, Polverino E, Quittner A, Ringshausen FC, Tino G, Torres A, Vendrell M, Welte T, Wilson R, Wong C, O’Donnell A, Aksamit T; EMBARC/BRR definitions working group. (2017). Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. Eur Respir J. 49(6):1700051. doi: 10.1183/13993003.00051-2017.
  8. Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, Murris M, Cantón R, Torres A, Dimakou K, De Soyza A, Hill AT, Haworth CS, Vendrell M, Ringshausen FC, Subotic D, Wilson R, Vilaró J, Stallberg B, Welte T, Rohde G, Blasi F, Elborn S, Almagro M, Timothy A, Ruddy T, Tonia T, Rigau D, Chalmers JD. (2017). European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 50(3):1700629. doi: 10.1183/13993003.00629-2017.